BioNTech stock

BNTX · NASDAQ · USD

Compare BioNTech
$84.86Change from previous close: −0.47%Absolute change: −$0.40

Close · November 17, 2026

Price history

−17.20% over the period

1 year: from $102.67 (November 17, 2025) to $85.02 (November 17, 2026), −17.20%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$85.02
October 30, 2026$88.17
September 30, 2026$98.30
August 31, 2026$101.61
July 31, 2026$90.58
June 30, 2026$93.05
May 29, 2026$95.95
April 30, 2026$103.45
March 31, 2026$88.88
February 27, 2026$110.23
January 30, 2026$113.75
December 31, 2025$95.20
November 28, 2025$103.15
November 17, 2025$102.67

At a glance

  • The company

    Develop and commercialize immunotherapies including mRNA vaccines and oncology drugs across multiple clinical trial phases

  • Latest results

    Quarter to September 30, 2026 · EPS €1.76 (estimate €0.78)

TickerLandia's take on BioNTech

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$79.52
52-wk high$124.00

−31.56% from the 52-week high

Analysts · 21 analysts

Average target$112.40+32.45% vs. price

Buy 14 · Hold 7 · Sell 0 · Buy

TickerLandia Fingerprint: BioNTech

Compared with similar companies: low price, weak momentum, and low profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

BioNTech is cheaper than similar companies

BioNTech's Price/book: 1.07, −87% against the median of a group of 10 similar companies (8.03).

Compared with 11 similar companies

BioNTech's metrics compared with similar companies
MetricBioNTechPosition in the groupBand
Operating margin-55.4%Low
ROE-8.1%Middle
Debt/equity0.02Low
Price/book1.07Low
Net margin-60.9%Low

Grey band: the middle half of the group; tick: the median; dot: BioNTech. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€105.6M

Latest quarter · Q2 2026

Net income

-€820.8M

Latest quarter · Q2 2026

Quarterly net margin

-777.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$21.22B
EPS
-$6.83
Volume
844.5K
Daily trading
€73.65M

How BioNTech is changing

All results
  • Revenue grew 42.9% a year on average over the last 5 years

  • Operating margin fell from 68.8% to −44.1%

  • Profitable in 3 of 5 fiscal years

Returns

BioNTech returns with dividends

$1,000 invested in BioNTech 5 years ago, on November 17, 2021, would be worth $317 today with dividends reinvested: −68.32% in total, −20.54% per year. On price alone it would be $313 (−68.74%).

PeriodBioNTechS&P 500$1,000 becomes
1 month−4.70%−3.17%$953
6 months−5.24%+0.11%$948
Year to date−10.70%+8.34%$893
1 year−17.20%+11.15%$828
3 years−14.46%+64.30%$855
5 years−68.32%+58.18%$317

Over the last 6 months it has done better than 16% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

BioNTech: technical analysis

BioNTech is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.0% below its all-time closing high ($447.23, August 9, 2021).

Trend
Downward
RSI (14 sessions)
39
Between 30 and 70
vs 200-session average
−11.12%

Support and resistance

Price areas where BioNTech has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$90.97+7.20%4 touches, last on November 4, 2026
  2. Resistance$88.13+3.85%6 touches, last on October 16, 2026
  3. Resistance$84.91+0.06%3 touches, last on October 27, 2026
  4. Last price$84.86
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
0.97
Volatility (60 sessions, annualised)
38.3%
Largest fall in the last year
−29.71%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

BioNTech: seasonality

Average monthly price change over 7 years

+1.4%Jan−3.8%Feb+5.8%Mar+7.7%Apr+2.9%May+3.8%Jun+12.4%Jul−2.7%Aug+1.3%Sep+0.5%Oct+19.3%Nov−3.3%Dec

Over the last 7 years, the strongest month for BioNTech has been November: +19.29% on average, positive in 6 years out of 7. The weakest has been February: −3.79% on average, positive in 1 years out of 7.

Show chart data
MonthAverageMedianPositive years
January+1.43%−4.53%3 of 7
February−3.79%−6.76%1 of 7
March+5.77%+0.15%4 of 7
April+7.69%−3.72%3 of 7
May+2.91%+4.32%4 of 7
June+3.78%+2.71%4 of 7
July+12.42%+7.27%6 of 7
August−2.71%+0.26%4 of 7
September+1.29%−3.26%2 of 7
October+0.55%+2.05%4 of 7
November+19.29%+21.35%6 of 7
December−3.34%−7.71%2 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

BioNTech and its competitors

The United States accounted for 62.5% of revenue in the fiscal year ended December 2025, ahead of Germany at 26.5% and Ireland at 10.6%. BioNTech SE, together with its subsidiaries, develops and commercializes immunotherapies, with its operations based in Germany. Its vaccine BNT162 is an mRNA product against SARS-CoV-2. The oncology pipeline includes drugs in Phase III trials, among them Gotistobart for metastatic non-small cell lung cancer and Pumitamig for small cell lung cancer, along with candidates for influenza, tuberculosis, malaria and mpox.

Headquarters
Mainz, Germany
Employees
7,807
Founded
2008
Chief executive
Ugur Sahin
BioNTech and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BioNTechBNTX$21.22B-55.4%—−5.24%
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−45.47%
IncyteINCY$24.36B32.2%61.0+24.95%
Ascendis PharmaASND$18.06B30.9%18.1+12.76%
InsmedINSM$26.96B-41.7%—+11.65%
ExelixisEXEL$16.37B40.2%20.1+36.64%

Same industry or related industries, similar size. Compare BioNTech with its competitors · Full profile